Based on the key indicators related to Zentalis Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Zentalis Pharmaceuticals Llc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Zentalis Pharmaceuticals' Other Assets are quite stable compared to the past year. Net Receivables is expected to rise to about 8.5 M this year, although the value of Total Current Liabilities will most likely fall to about 40.3 M. Key indicators impacting Zentalis Pharmaceuticals' financial strength include:
Investors should never underestimate Zentalis Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Zentalis Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Zentalis Pharmaceuticals Llc.
Net Income
(249.82 Million)
Zentalis
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Non Current Liabilities Other
Net Working Capital
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Short Term Debt
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Short Term Investments
Capital Surpluse
Tax Provision
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Minority Interest
Cost Of Revenue
Probability Of Bankruptcy
Understanding current and past Zentalis Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Zentalis Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Zentalis Pharmaceuticals' assets may result in an increase in income on the income statement.
Zentalis Pharmaceuticals competes with Sana Biotechnology, Olema Pharmaceuticals, Cullinan Oncology, Monte Rosa, and Design Therapeutics. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Zentalis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Zentalis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zentalis Pharmaceuticals competition to find correlations between indicators driving Zentalis Pharmaceuticals's intrinsic value. More Info.
Zentalis Pharmaceuticals Llc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Zentalis Pharmaceuticals' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Zentalis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Zentalis Pharmaceuticals Systematic Risk
Zentalis Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Zentalis Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Zentalis Pharmaceuticals correlated with the market. If Beta is less than 0 Zentalis Pharmaceuticals generally moves in the opposite direction as compared to the market. If Zentalis Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Zentalis Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Zentalis Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Zentalis Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Zentalis Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Zentalis Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Zentalis Pharmaceuticals growth as a starting point in their analysis.
Zentalis Pharmaceuticals February 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Zentalis Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Zentalis Pharmaceuticals Llc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Zentalis Pharmaceuticals Llc based on widely used predictive technical indicators. In general, we focus on analyzing Zentalis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Zentalis Pharmaceuticals's daily price indicators and compare them against related drivers.
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.50)
Revenue Per Share
0.572
Return On Assets
(0.25)
Return On Equity
(0.43)
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.